

Melanie R Hassler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6939358/publications.pdf>

Version: 2024-02-01

33
papers

841
citations

623188

14
h-index

500791

28
g-index

33
all docs

33
docs citations

33
times ranked

1855
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations. <i>Current Opinion in Urology</i> , 2022, 32, 48-53.	0.9	4
2	Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. <i>Molecular Cancer</i> , 2022, 21, 7.	7.9	10
3	Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. <i>European Urology</i> , 2022, 82, 261-270.	0.9	11
4	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 1683-1686.	1.6	4
5	Thyroid and androgen receptor signaling are antagonized by Î³4â€Crystallin in prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 731-747.	2.3	17
6	Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. <i>European Urology Open Science</i> , 2021, 30, 63-66.	0.2	4
7	Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations. <i>Journal of Personalized Medicine</i> , 2021, 11, 1147.	1.1	1
8	Impact of Patientsâ€™ Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 88-94.e2.	0.9	22
9	Epigenetic alterations of testicular germ cell tumours. <i>Current Opinion in Urology</i> , 2020, 30, 264-270.	0.9	7
10	Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. <i>Cells</i> , 2020, 9, 1839.	1.8	11
11	Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. <i>Current Opinion in Urology</i> , 2020, 30, 519-526.	0.9	15
12	PD1/PD-L1 therapy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2020, 30, 534-541.	0.9	8
13	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. <i>European Urology</i> , 2020, 78, 209-220.	0.9	66
14	The prognostic impact of tumour NSD2 expression in advanced prostate cancer. <i>Biomarkers</i> , 2020, 25, 268-273.	0.9	6
15	A systematic review and metaâ€analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. <i>BJU International</i> , 2019, 123, 11-21.	1.3	45
16	Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 389-394.	0.9	3
17	Nonmuscle invasive urothelial cancerâ€™ Bacillus Calmetteâ€™Guerin instillation or checkpoint inhibitor immunotherapy?. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 319-323.	0.3	1
18	Salvage therapeutic strategies for bacillus Calmetteâ€™Guerin failure. <i>Current Opinion in Urology</i> , 2019, 29, 239-246.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. <i>European Urology</i> , 2019, 75, 649-658.	0.9	82
20	Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 347-356.	1.5	12
21	Tissue biomarkers in nonmuscle-invasive bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 584-590.	0.9	6
22	Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 695-703.	1.1	11
23	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 356-362.	0.8	4
24	An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. <i>Biomolecules</i> , 2016, 6, 37.	1.8	44
25	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 533.e1-533.e10.	0.8	17
26	Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling. <i>Cell Reports</i> , 2016, 17, 596-608.	2.9	55
27	The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant <i>Neurolaena lobata</i> (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF- κ B-driven tumour intravasation. <i>Phytomedicine</i> , 2015, 22, 862-874.	2.3	9
28	STAT3 regulated ARF expression suppresses prostate cancer metastasis. <i>Nature Communications</i> , 2015, 6, 7736.	5.8	136
29	Lobatin B inhibits NPM/ALK and NF- κ B attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation. <i>Cancer Letters</i> , 2015, 356, 994-1006.	3.2	8
30	Brain-derived neurotrophic factor (BDNF) Epigenetic regulation in unipolar and bipolar affective disorder. <i>Journal of Affective Disorders</i> , 2014, 168, 399-406.	2.0	74
31	Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma. <i>Epigenomics</i> , 2013, 5, 397-415.	1.0	16
32	Epigenomics of cancer – emerging new concepts. <i>Biochimie</i> , 2012, 94, 2219-2230.	1.3	70
33	Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma. <i>Biochimie</i> , 2012, 94, 2297-2307.	1.3	51